MapLight Therapeutics ratios data for the quarter ended Jun 2026. These financial ratios cover 2 quarters of results from Dec 2025 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Dec2025 | Jun2026 |
|---|---|---|
| Efficiency | ||
| Assets AverageAssets Avg. | 368.37M | 423.93M |
| Valuation | ||
| Price to EarningsP/E | -1.89 | -26.61 |
| Price to BookP/B | 0.33 | 4.68 |
| Enterprise Value | -152.58M | 1,323.73M |
| EV to EBIT | 1.83 | -20.83 |
| EV to EBITDA | 1.83 | -20.83 |
| Market Capitalization | 152.52M | 1,628.46M |
| Price to FCFP/FCF | -3.23 | |
| EV to FCF | 3.23 | |
| EV to CFO | 3.26 | |
| Return Ratios | ||
| Return on Capital Employed [ROCE]ROCE | -47.80% | -51.67% |
| Return on Assets [ROA]ROA | -44.17% | -47.66% |